In today’s healthcare system, drug decisions are often driven by manufacturer rebates rather than clinical evidence—creating a disconnect between cost and patient outcomes. VIVIO’s SVP of Clinical Programs, Samuel Kabue, PharmD, and VIVIO’s Director of Clinical Programs, Michelle Lee, PharmD will unpack how a data-driven, personalized approach can fundamentally reshape both clinical results and total cost of care. We’ll walk through real-world outcomes for complex therapeutic areas like HIV and psoriasis, where VIVIO’s data-driven therapy selection has demonstrated measurable success.